LFB’s commitments to patients, with AFNP association

LFB alongside the ADAAT association

2022 LFB corporate Brochure

LFB CSR Charter

LFB’s Modern Slavery Statement (English)

THE LFB IN PICTURES

2020 LFB NON FINANCIAL PERFORMANCE STATEMENT

The LFB in pictures

AFH web documentary on Von Willebrand disease

More information about the LFB site in Alès

LFB Research Grant in Immunology 2021

Scientific publications for LFB

LFB Arras plant under construction in October 2020 in video

CAHPP green index: LFB obtains A++ label

2021 LFB corporate Brochure

An ENVIRONMENTAL RESPONSIBILITY

LFB’s commitment to patients with IRIS

2019 LFB NON-FINANCIAL PERFORMANCE STATEMENT

Presentation of PRISM Study results at the ICNMD 2020 virtual congress

Arras plant visit

LFB symposium at the ISTH virtual congress on July 14th 2020

Presentation of LFB PRISM study posters, at the PNS congress on 27 June 2020

FDA approval for SEVENFACT® the LFB recombinant Factor VIIa

Les valeurs LFB

Agreement with Xenothera to manufacture a treatment for CORONAVIRUS INFECTIONS INCLUDING COVID-19

FDA approval for the LFB recombinant coagulation Factor VIIa

Discover the LFB Arras plant under construction – September 2019

LFB 2018 NON-FINANCIAL PERFORMANCE STATEMENT

Key dates

More information on LFB

LFB completes the sale of CELLforCURE to Novartis

LFB strategic transformation project

Relations with patients’ associations in 2019

Relations with French patients’ associations (2017)

Relations with patients’ associations (2017)

Living with peripheral neuropathies, an AFNP video supported by LFB

2016 LFB Annual Report : download the PDF

Inauguration of new industrial facilities at the LFB biotech plant in Alès (Gard)

CELLforCURE manufacturing partner of Cellectis for the manufacture of UCART123

LFB’s fibrinogen and 10% immunoglobulin authorized for use in Europe

Découvrez le webdocumentaire de l’AFH sur la maladie de Willebrand

Acceptance of the filed BLA for LFB’s rFVIIa

“Usine 2020” LFB : laying of the foundation stone by the French President (7th June 2016)

Biological safety of plasma-derived medicinal products

20 january 2016: CELLforCURE enters into new agreement with Cellectis

22 february 2016: Registration of FibCLOT®, LFB’s human fibrinogen, in Europe

31 march 2016: LFB chooses Technip as prime-contractor for “Usine 2020”

Strategic committee of LFB BIOTECHNOLOGIES

Relations with patients associations in France (2016)

Composition of the LFB Biotechnologies Board

Composition of the LFB BIOMEDICAMENTS Board of Directors

2020 plant: virtual visit

How are cell-therapy medicinal products produced?

How are recombinant medicinal products produced by cell culture?

How are plasma derivatives produced?

Regulatory report on LFB’s greenhouse gas emissions for France – In French (2014)

8 July 2011: LFB is granted a US patent for its highly active monoclonal antibodies

30 September 2013: funding for a new French biotechnology company specialising in cancer

Technology transfer: agreement LFB – STROVI (Malaysia)

rEVO Biologics is collaborating with Yale University on pre-eclampsia research

09 June 2014: CELLECTIS signs a production agreement with CELLforCURE reflecting cGMP standards, to produce allogenic CAR-T lymphocytes

rFVIIa : ACHIEVEMENT OF PATIENT ENROLLMENT TARGET FOR PERSEPT 1

22 September 2015: first MAs in Europe for IQYMUNE®

1 July 2015: LFB’s “Plant 2020”, a “made in France” facility producing for the whole world.

12 October 2015: LFB S.A. is increasing its capital by 230 million euros.

Technology transfer

LFB Group corporate film

HEMOSIMS®, simulation training

Relations with patients’ associations (2016)

LFB’s commitment to its employees

LFB: 4th best employer in the pharmaceutical sector in France

LFB gender equality policy in France (in French)

IPIC: a major immunology congress

Orphanet

Understanding nanofiltration

Atryn®, a medicinal product developed by rEVO Biologics

LFB USA, a subsidiary specialising in biotechnology

LFB BIOMEDICAMENTS: a public health mission in France

Ensuring the biosafety of LFB’s plasma derivatives

The LFB group’s position on the risk of sCJD – January 2012

LFB in Brazil

LFB BIOMANUFACTURING doubles its production capacity

Understand rPRO™ technology

Rare disorders of pregnancy

Understanding congenital coagulation disorders

Understanding primary immunodeficiency

15 June 2014: BFM TV report on LFB for World Blood Donor Day

An enduring commitment to the field of rare diseases

The LFB innovation policy

2015 annual report: download the pdf

Key figures for the Group (2016)